Presentations & Publications
ATTR-CM
This page may contain non-exhaustive scientific information about post-hoc, exploratory, subgroup analyses, or uses that have not yet been approved by regulatory authorities. The information is provided for educational and scientific exchange purposes, and does not suggest products should be used in a manner not consistent with their respective label approved by the regulatory authorities, which may differ by geography. Any publication reflects the state of knowledge at the time it was published. The information is not medical advice and cannot replace the independent medical judgement of a healthcare professional.
Month
Year
Content Type
Evidence Type
Real World Evidence · Sep 2026
Cardiology and Therapy, Real-World Outcomes With Acoramidis and Tafamidis in ATTR-CM (opens an external site)
Presentation · Aug 2026 · PDF
ESC 2026, A Novel AI-Derived Digital Biomarker for Monitoring Disease Progression in ATTR-CM, Khera
Presentation · Nov 2025 · PDF
AHA 2025, Geographic Disparities in Transthyretin Amyloid Cardiomyopathy Prevalence in United States Veterans, Dev
Presentation · Sep 2025 · PDF
HFSA 2025, Effect of Acoramidis on Cardiac Conduction Abnormalities in Transthyretin Amyloid Cardiomyopathy, Sperry
Presentation · May 2025 · PDF
PNS 2025, Low Transthyretin Is Associated With Severe Comorbidities: Insights From the UK Biobank, Khella
Presentation · Apr 2025 · PDF
ACC 2025, Acoramidis-Mediated Early Increase in Serum Transthyretin: Insights From the ATTRibute-CM Study, Sarswat
Presentation · Apr 2025 · PDF
ACC 2025, Acoramidis in ATTRibute-CM: Prespecified NT-proBNP Sensitivity Analyses of the Primary Endpoint, Griffin
Presentation · Apr 2025 · PDF
ACC 2025, NYHA Class at Month 30 With Acoramidis in Patients With ATTR-CM: Results From ATTRibute-CM, Alexander
Presentation · Dec 2024 · PDF
AHA 2024, Relationship Between CVH and Survival in the Acoramidis-Treated Participants Within ATTRibute-CM, Alexander
Presentation · Dec 2024 · PDF
ISA 2024, Higher Risk of Mortality in Previously Hospitalized Patients: Insights From ATTRibute-CM, Masri
Presentation · Dec 2024 · PDF
ESC-HF 2024, Acoramidis and NT-proBNP in ATTR-CM: Insights From the ATTRibute-CM Study, Garcia-Pavia
Presentation · Dec 2024 · PDF
ESC-HF 2024, Health-Related Quality of Life in Patients With ATTR-CM Treated With Acoramidis: KCCQ Results, Fontana
Presentation · Sep 2024 · PDF
ACC 2026, Contemporary Oral Medication Usage and Frequency in Patients With Transthyretin Cardiac Amyloidosis, Dasgupta
Presentation · Dec 2023 · PDF
AHA 2023, Clinical Outcomes With Acoramidis in Transthyretin Amyloid Cardiomyopathy, Judge
Presentation · Dec 2023 · PDF
ESC 2023, Acoramidis in Transthyretin Amyloid Cardiomyopathy: Results of the ATTRibute-CM Trial, Gillmore
No results found.